Annual Drug Patent Expiration for BYDUREON
Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from a single supplier. There are twenty-three patents protecting this drug.
BYDUREON drug price trends.
Drug patent litigation for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. One registered supplier for this compound. Additional details are available on the exenatide synthetic profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published on new patent expiry for the drug Astrazeneca Ab BYDUREON